Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Advances in specific therapy for multiple sclerosis

L Jacobs1, D E Goodkin, R A Rudick

  • 1Baird Multiple Sclerosis Center, Buffalo, New York.

Current Opinion in Neurology
|June 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A roadmap for kidney health for South Africa in the context of universal health coverage.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2025
Same author

Crescent-shaped plaques on the shins.

The American journal of medicine·2025
Same author

Public and industry knowledge and perceptions of US swine industry castration practices.

Animal welfare (South Mimms, England)·2024
Same author

Estimates of Current Capacity for Diagnosing Alzheimer's Disease in Sweden and the Need to Expand Specialist Numbers.

The journal of prevention of Alzheimer's disease·2024
Same author

Social-pair judgment bias testing in slow-growing broiler chickens raised in low- or high-complexity environments.

Scientific reports·2023
Same author

Enhancing their quality of life: environmental enrichment for poultry.

Poultry science·2022

Two new multiple sclerosis treatments, interferon beta and methylprednisolone, show promise. Interferon beta reduces relapses and lesions, while methylprednisolone delays disease development in optic neuritis patients.

Area of Science:

  • Neurology
  • Immunology

Background:

  • Multiple sclerosis (MS) is a chronic neurological disease.
  • Effective treatments for MS have been limited.

Purpose of the Study:

  • To review recent advancements in multiple sclerosis treatment.
  • To highlight the efficacy of two new agents: recombinant interferon beta and methylprednisolone.

Main Methods:

  • Review of clinical data on recombinant interferon beta (Betaseron).
  • Analysis of studies on high-dose methylprednisolone for optic neuritis patients.

Main Results:

  • Recombinant interferon beta reduces MS relapses and brain lesions but not disability.
  • Methylprednisolone significantly decreases the conversion rate of optic neuritis to MS.

Related Experiment Videos

  • Both agents impact the immune system, though mechanisms are not fully understood.

    • Conclusions:

    • Recombinant interferon beta and methylprednisolone represent significant progress in MS treatment.
    • These agents offer prophylaxis against relapses and may delay disease progression.
    • Further research into other therapies like copolymer 1 and methotrexate is ongoing.